CoChat

The mechanism, efficacy, and tolerability profile of agomelatine

MacIsaac, Sarah E, Carvalho, André F, Cha, Danielle S, Mansur, Rodrigo B, McIntyre, Roger S · 2014 · Expert Opinion on Pharmacotherapy
Cited by 24

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Agomelatine is a novel antidepressant that acts as a melatonin MT1 and MT2 receptor agonist and serotonin 5-HT2C receptor antagonist, putatively reversing circadian rhythm disruption in major depressive disorder (MDD) and promoting dendritic neurogenesis in animal models of depression. It may be a preferable alternative to antidepressants currently in use due to its improved tolerability profile. AREAS COVERED: The PubMed database was searched for published randomized controlled trials (RCTs) evaluating the efficacy of agomelatine as well as its tolerability and safety in the treatment of MDD. The key search term used was agomelatine combined with major depressive disorder/depressive disorder/depression and antidepressant. Article selection was based upon sample size and overall methodological quality. EXPERT OPINION: Agomelatine is a multi-modal agent with novel mechanisms of action, having sound evidence supporting its overall statistical efficacy and adequate tolerability profile for MDD treatment. However, the clinical significance of agomelatine has been contested, calling for additional studies in evaluation of its effect size. Of further concern are reported transient elevations in transaminases and severe but rare liver reactions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14656566.2014.862233

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 24

Metadata

Authors
MacIsaac, S. E., Carvalho, A. F., Cha, D. S., Mansur, R. B., & McIntyre, R. S.
Venue
Expert Opinion on Pharmacotherapy
Published
2013-12-16
Volume
15
Issue
2
Pages
259-274
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W2114843189
Cited by
24
References
12
FWCI
1.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The mechanism, efficacy, and tolerability profile of agomelatine. https://app.cochat.ai/papers/10.1517/14656566.2014.862233
The paper
MacIsaac, S. E., Carvalho, A. F., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014). The mechanism, efficacy, and tolerability profile of agomelatine. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2014.862233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.